ADC Therapeutics SA (NYSE: ADCT) is set to provide an update on preliminary data from its LOTIS-7 Phase 1b open-label clinical trial, evaluating the combination of ZYNLONTA® (loncastuximab tesirine-lpyl) and glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The company will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m. EST to share the results.
The LOTIS-7 trial is designed to assess the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab in patients with r/r DLBCL who have undergone two or more lines of systemic therapy. DLBCL is an aggressive form of non-Hodgkin lymphoma, and patients who relapse or are refractory to initial treatments face a poor prognosis, highlighting the unmet medical need for more effective therapies.
ZYNLONTA®: A Key Component
ZYNLONTA®, ADC Therapeutics' CD19-directed antibody-drug conjugate (ADC), has already received accelerated approval from the FDA and conditional approval from the European Commission for the treatment of r/r DLBCL after two or more lines of systemic therapy. This approval was based on promising results demonstrating its efficacy in heavily pre-treated patients. The drug is also being explored in combination with other agents and in earlier lines of therapy.
Conference Call Details
Interested parties can access the conference call by registering via a provided link. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website. The archived webcast will be available for 30 days following the call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody-drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey.
